HC Wainwright Reaffirms “Neutral” Rating for Pliant Therapeutics (NASDAQ:PLRX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. A number of other research analysts also recently weighed in on PLRX. Citigroup lowered their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating on the […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. A number of other research analysts also recently weighed in on PLRX. Citigroup lowered their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating on the […]
